東京科学大学 · 医歯学総合研究科 · 准教授

研究キーワードulcerative colitis・Crohn disease・anti-integrin alphaVbeta6・serum biomarker・first-line biologics・multicenter trial

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• Muneyori Okita, Kento Takenaka, Fumihito Hirai, Shinya Ashizuka, Hideki Iijima, Shigeki Bamba, Toshimitsu Fujii, Kenji Watanabe, Yosuke Shimodaira, Hisashi Shiga, Sakiko Hiraoka, Toshihiro Inokuchi, Takeshi Yamamura, Ryo Emoto, Shigeyuki Matsui. Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn's disease activity in the small bowel. J Gastroenterol. 2025.05; 60 (5): 573-582. ( PubMed , DOI )2025
• Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study. Intest Res. 2024.07; 22 (3): 369-377. ( PubMed , DOI )2024
• Xiang Gao, Toshimitsu Fujii, Byong Duk Ye, Jen-Wei Chou, Ken Sugimoto, Qian Cao, Kristina Kligys, Kaoru Murakoshi, Dennis Teng, Yafei Zhang, Hiroshi Nakase. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Gastroenterol Hepatol. 2024.01; 39 (1): 55-65. ( PubMed , DOI )2024
• Marc Ferrante, Peter M Irving, Maria T Abreu, Jeffrey Axler, Xiang Gao, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Joana Torres, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Sofie Berg, Xiaomei Liao, Qing Zhou, Jasmina Kalabic, Brian Feagan, Remo Panaccione. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. J Crohns Colitis. 2024.03; 18 (3): 416-423. ( PubMed , DOI )2024

• 公式プロフィール